{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:01:11Z","timestamp":1789570871189,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Heart failure (HF) is associated with poor prognosis, high morbidity and mortality. The prognosis can be optimised by guideline adherence, which also can be used as a\u00a0benchmark of quality of care. The purpose of this study was to evaluate differences in use of HF medication between Dutch HF clinics.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The current analysis was part of a\u00a0cross-sectional registry of 10,910 chronic HF patients at 34\u00a0Dutch outpatient clinics in the period of 2013 until 2016 (CHECK-HF), and focused on the differences in prescription rates between the participating clinics in patients with heart failure with reduced ejection fraction (HFrEF).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A\u00a0total of 8,360 HFrEF patients were included with a\u00a0mean age of 72.3\u202f\u00b1\u200911.8\u00a0years (ranging between 69.1\u202f\u00b1\u200911.9 and 76.6\u202f\u00b1\u200910.0 between the clinics), 63.9% were men (ranging between 54.3 and 78.1%), 27.3% were in New York Heart Association (NYHA) class\u00a0III\/IV (ranging between 8.8 and 62.1%) and the average estimated glomerular filtration rate (eGFR) was 59.6\u202f\u00b1\u200924.6\u202fml\/min (ranging between 45.7\u202f\u00b1\u200923.5 and 97.1\u202f\u00b1\u200916.5).<\/jats:p>\n<jats:p>The prescription rates ranged from 58.9\u201397.4% for beta blockers (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01), 61.9\u201397.1% for renin-angiotensin system (RAS) inhibitors (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01), 29.9\u201386.8% for mineralocorticoid receptor antagonists (MRAs) (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01), 0.0\u201331.3% for ivabradine (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01) and 64.9\u2013100.0% for diuretics (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01). Also, the percentage of patients who received the target dose differed significantly, 5.9\u201329.1% for beta blockers (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01), 18.4\u201356.1% for RAS inhibitors (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01) and 13.2\u201360.6% for MRAs (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090.01).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The prescription rates and prescribed dosages of guideline-recommended medication differed significantly between HF outpatient clinics in the Netherlands, not fully explained by differences in patient profiles.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s12471-020-01421-1","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T14:19:16Z","timestamp":1589897956000},"page":"334-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry"],"prefix":"10.1007","volume":"28","author":[{"name":"CHECK-HF investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. C. M.","family":"Linssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Veenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Brunner-La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. E. J.","family":"van Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J. M.","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"van Tooren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J. J.","family":"Koornstra-Wortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W.","family":"Hoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Brugts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","volume":"390","author":"M Metra","year":"2017","unstructured":"Metra\u00a0M, Teerlink\u00a0JR. Heart failure. Lancet. 2017;390:1981\u201395.","journal-title":"Lancet"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/ejhf.709","volume":"19","author":"S Koudstaal","year":"2017","unstructured":"Koudstaal\u00a0S, Pujades-Rodriguez\u00a0M, Denaxas\u00a0S, et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a\u00a0population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017;19:1119\u201327.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/ejhf.30","volume":"16","author":"VM van Deursen","year":"2014","unstructured":"van Deursen\u00a0VM, Urso\u00a0R, Laroche\u00a0C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16:103\u201311.","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"1421_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray\u00a0JJ, Adamopoulos\u00a0S, Anker\u00a0SD, et\u00a0al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J. 2012;33:1787\u2013847.","journal-title":"Eur Heart J"},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD, et\u00a0al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891\u2013975.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ejhf.1459","volume":"21","author":"M Komajda","year":"2019","unstructured":"Komajda\u00a0M, Sch\u00f6pe\u00a0J, Wagenfleil\u00a0S, et al. Physicians\u2019 guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2019;21:921\u20139.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10741-019-09777-2","volume":"24","author":"WJ Kruik-Koll\u00f6ffel","year":"2019","unstructured":"Kruik-Koll\u00f6ffel\u00a0WJ, Linssen\u00a0GCM, Kruik\u00a0HJ, et al. Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015. Heart Fail Rev. 2019;24:499\u2013510.","journal-title":"Heart Fail Rev"},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ejhf.566","volume":"18","author":"MG Crespo-Leiro","year":"2016","unstructured":"Chioncel O, Lainscak M, Seferovic PM et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574\u201385.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene\u00a0SJ, Butler\u00a0J, Albert\u00a0NM, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF Registry. J\u00a0Am Coll Cardiol. 2018;72:351\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1421_CR10","first-page":"13","volume":"7","author":"HP Brunner-La Rocca","year":"2019","unstructured":"Brunner-La Rocca\u00a0HP, Linssen\u00a0GC, Smeele\u00a0FJ, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction. The CHECK-HF registry. J\u00a0Am Coll Cardiol. 2019;7:13\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"1421_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather\u00a0MD, Shibata\u00a0MC, Coats\u00a0AJ, et\u00a0al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart\u00a0J. 2005;26:215\u201325.","journal-title":"Eur Heart J"},{"key":"1421_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","volume":"297","author":"HG Van Spall","year":"2007","unstructured":"Van Spall\u00a0HG, Toren\u00a0A, Kiss\u00a0A, Fowler\u00a0RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a\u00a0systematic sampling review. JAMA. 2007;297:1233\u201340.","journal-title":"JAMA"},{"issue":"e003529","key":"1421_CR13","first-page":"1","volume":"10","author":"H Burnett","year":"2017","unstructured":"Burnett\u00a0H, Earley\u00a0A, Voors\u00a0AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a\u00a0network meta-analysis. Circ Heart Fail. 2017;10(e003529):1.","journal-title":"Circ Heart Fail"},{"key":"1421_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s12471-018-1103-7","volume":"26","author":"JJ Brugts","year":"2018","unstructured":"Brugts\u00a0JJ, Linssen\u00a0GCM, Hoes\u00a0AW, Brunner-La Rocca\u00a0HP, Investigators of CHECK-HF. Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry. Neth Heart\u00a0J. 2018;26:272\u20139.","journal-title":"Neth Heart J"},{"key":"1421_CR15","first-page":"13","volume":"7","author":"HP Brunner-La Rocca","year":"2019","unstructured":"Brunner-La Rocca\u00a0HP, Linssen\u00a0GC, Smeele\u00a0FJ, et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction. The CHECK-HF registry. J\u00a0Am Coll Cardiol. 2019;7:13\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"1421_CR16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1177\/2047487319835042","volume":"26","author":"JF Veenis","year":"2019","unstructured":"Veenis\u00a0JF, Brunner-La Rocca\u00a0HP, Linssen\u00a0GC, et al. CHECK-HF investigators. Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. Eur J Prev Cardiol. 2019;26:1399\u2013407.","journal-title":"Eur J Prev Cardiol"},{"key":"1421_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","volume":"20","author":"G Savarese","year":"2018","unstructured":"Savarese\u00a0G, Carrero\u00a0JJ, Pitt\u00a0B, et\u00a0al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20:1326\u201334.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/ejhf.900","volume":"19","author":"JP Ferreira","year":"2017","unstructured":"Ferreira\u00a0JP, Rossignol\u00a0P, Machu\u00a0JL, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail. 2017;19:1284\u201393.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR19","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1093\/eurheartj\/ehy621","volume":"39","author":"G Savarese","year":"2018","unstructured":"Savarese\u00a0G, Dahlstr\u00f6m\u00a0U, Vasko\u00a0P, et al. Association between renin-angiotensin system inhibitor use and mortality\/morbidity in elderly patients with heart failure with reduced ejection fraction: a\u00a0prospective propensity score-matched cohort study. Eur Heart\u00a0J. 2018;39:4257\u201365.","journal-title":"Eur Heart J"},{"key":"1421_CR20","first-page":"52","volume":"33","author":"HP Brunner-La Rocca","year":"2012","unstructured":"Brunner-La Rocca\u00a0HP, Rickenbacher\u00a0P, Muzzarelli\u00a0S, et al. End-of-life preferences of elderly patients with chronic heart failure. Eur Heart\u00a0J. 2012;33:52\u20139.","journal-title":"Eur Heart J"},{"key":"1421_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/S0140-6736(19)31792-1","volume":"394","author":"BT Santema","year":"2019","unstructured":"Santema\u00a0BT, Ouwerkerk\u00a0W, Tromp\u00a0J, et\u00a0al. Identifying optimal doses of heart failure medications in men compared with women: a\u00a0prospective, observational, cohort study. Lancet. 2019;394:1254\u201363.","journal-title":"Lancet"},{"key":"1421_CR22","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk\u00a0W, Voors\u00a0AA, Anker\u00a0SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a\u00a0prospective European study. Eur Heart\u00a0J. 2017;38:1883\u201390.","journal-title":"Eur Heart J"},{"key":"1421_CR23","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/ejhf.401","volume":"17","author":"HP Brunner-La Rocca","year":"2015","unstructured":"Brunner-La Rocca\u00a0HP, Eurlings\u00a0L, Richards\u00a0AM, et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail. 2015;17:1252\u201361.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s12471-015-0722-5","volume":"23","author":"CMHB Lucas","year":"2015","unstructured":"Lucas\u00a0CMHB, van Pol\u00a0PEJ, Eysink Smeets\u00a0JBE, et\u00a0al. Heart failure in 2015: let\u2019s get organised! Neth Heart\u00a0J. 2015;23:447\u20139.","journal-title":"Neth Heart J"},{"key":"1421_CR25","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","volume":"393","author":"P Rossignol","year":"2019","unstructured":"Rossignol\u00a0P, Hernandez\u00a0AF, Solomon\u00a0SD, Zannad\u00a0F. Heart failure drug treatment. Lancet. 2019;393:1034\u201344.","journal-title":"Lancet"},{"key":"1421_CR26","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/ejhf.915","volume":"19","author":"AP Ambrosy","year":"2017","unstructured":"Ambrosy\u00a0AP, Gheorghiade\u00a0M. Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement. Eur J Heart Fail. 2017;19:1424\u20136.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","volume":"71","author":"CW Yancy","year":"2018","unstructured":"Yancy\u00a0CW, Januzzi\u00a0JL Jr, Allen\u00a0LA, et\u00a0al. 2017 ACC Expert Consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a\u00a0report of the American College of Cardiology Task Force on expert consensus decision pathways. J\u00a0Am Coll Cardiol. 2018;71:201\u201330. Erratum in: J Am Coll Cardiol. 2018;72:2549.","journal-title":"J Am Coll Cardiol"},{"key":"1421_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ejhf.1351","volume":"21","author":"CN Marti","year":"2019","unstructured":"Marti\u00a0CN, Fonarow\u00a0GC, Anker\u00a0SD, et\u00a0al. Medication dosing for heart failure with reduced ejection fraction\u2014opportunities and challenges. Eur J Heart Fail. 2019;21:286\u201396.","journal-title":"Eur J Heart Fail"},{"key":"1421_CR29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE, et\u00a0al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med. 2019; https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"1421_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ejhf.1503","volume":"21","author":"M Schulz","year":"2019","unstructured":"Schulz\u00a0M, Griese-Mammen\u00a0N, Anker\u00a0SD, et al. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. Eur J Heart Fail. 2019;21:1012\u201321.","journal-title":"Eur J Heart Fail"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-020-01421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-020-01421-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-020-01421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:01:40Z","timestamp":1621382500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-020-01421-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1007\/s12471-020-01421-1","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"19 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.P.\u00a0Brunner-La Rocca has received research grants from Roche Diagnostics, Novartis, and Vifor. G.C.M.\u00a0Linssen, J.F.\u00a0Veenis, P.E.J.\u00a0van Pol, D.J.M.\u00a0Engelen, R.M.\u00a0van Tooren, H.J.J.\u00a0Koornstra-Wortel, A.W.\u00a0Hoes and J.J.\u00a0Brugts declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}